XOMA Royalty Corp

Products & Services

Company Description

XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company that discovers, develops antibody-based therapeutics. Its lead product, gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include X358, X213 and X129. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 (formerly LFA 102) is an allosteric inhibitor of prolactin action; X129 is a potent fragment of a monoclonal antibody with negative allosteric modulation activity. Xoma has developed its proprietary antibody discovery, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. Xoma is headquartered in Berkeley, California, the US.The company reported revenues of (US Dollars) US$5.6 million for the fiscal year ended December 2016 (FY2016), a decrease of 90% over FY2015. The operating loss of the company was US$61.6 million in FY2016, compared to an operating loss of US$39.7 million in FY2015. The net loss of the company was US$53.5 million in FY2016, compared to a net loss of US$20.6 million in FY2015.

Business Contact Information

Phone

+1 (510) 2047200

Fax

+XXX (510) 6442011

Website

http://www.xoma.com

LinkedIn

linkedin.com/company/xoma

Facebook

facebook.com/xomacorporation

Address

2200 Powell St, Emeryville, California, 94608, United States

Industry & Classification

Industry Name Level 1

Financial

Industry Name Level 2

Finance

Industry Name Level 3

Investement Management

Company Details

Employees

13 (11-20)

Annual Revenue

$12.6M ($10M-$25M)

Established

No data

Total Funding

No data

Latest Funding

No data

Related Companies